- Scientific Programme
- Call for Abstracts
- General Information
- Industry Involvement
- Scientific Posters
- Scientific Abstracts
- Useful Links
- HIV Research Trust
The Organising Secretariat would like to thank the following companies whose continued support in the provision of unrestricted educational funding has been of great value in establishing the HIV Glasgow Congress.
50-100 Holmers Farm Way, High Wycombe, HP12 4DP, UK
At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com/uk and follow us at @JanssenUK. Janssen-Cilag Ltd is part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
2000 Galloping Hill Road,
Kenilworth, NJ 07033, USA
Our Commitment to HIV
For more than 30 years, Merck has been committed to scientific research and discovery in HIV and we continue to be driven by the conviction that more medical advances are still to come. Our focus is on pursuing research that addresses unmet medical needs and helps people living with HIV and their communities. We are making choices, including in our HIV pipeline, that could potentially change the HIV treatment and prevention paradigms, and help bring us closer to the goal of finding a cure. We remain committed to working hand-in-hand with our partners in the global HIV community to address the complex challenges to continued progress. For more information, visit www.msd.com.
GSK House, 980 Great West Road,
12th Floor, Brentford, Middlesex, TW8 9GS, UK
About ViiV Healthcare
ViiV Healthcare LLC is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV. Shionogi joined as a shareholder in October 2012. The company’s aim is to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and new HIV medicines, as well as support communities affected by HIV. For more information on the company, its management, portfolio, pipeline, and commitment, please visit www.viivhealthcare.com.